Determination of epirubicin and its metabolite epirubicinol in saliva and plasma by HPLC.
We present a high-performance liquid chromatography (HPLC) method suitable for the analysis of epirubicin and its metabolite epirubicinol in saliva and plasma. Preparation of saliva and plasma samples was performed by extraction of analytes with a chloroform:2-propanol mixture (6:1, vol/vol) and evaporation of the organic phase to dryness under vacuum at a temperature of approximately 45 degrees C. The chromatographic analysis was carried out by reversed-phase isocratic elution of the anthracyclines with a Chromsep stainless steel HPLC column (150 x 4.6 mm I.D.) filled with Nucleosil 100 S C(18) material, particle size 5 micro m. The detection was accomplished by spectrofluorimetry at excitation and emission wavelengths of 474 and 551 nm, respectively. The anthracyclines eluted within 10 min of injection, and the method appeared to be specific. The method is linear over a concentration range of 5 to 1000 micro g/L for epirubicin and 2 to 400 micro g/L for epirubicinol (r > 0.99) in both saliva and plasma. The recoveries from saliva and plasma of epirubicin, epirubicinol, and the internal standard doxorubicin were 88.9 and 69.0%, 87.6 and 77.3%, and 80 and 67.9%, respectively. The lower limit of quantification was 5 micro g/L for epirubicin and 2 micro g/L for epirubicinol. The method proved to be precise and accurate, as the within-day and between-day coefficients of variation were less than 10%. Overall results indicate that our method is suitable for the bioanalysis of epirubicin and epirubicinol in saliva as well as plasma.
Dodde
Wilma I W
WI
Laboratory for Drug Analysis and Toxicology, Department of Pharmacy, University Hospital Groningen, 9700 RB Groningen, The Netherlands.
Maring
Jan Gerard
JG
Hendriks
Gert
G
Wachters
Floris M
FM
Groen
Harry J M
HJ
de Vries
Elisabeth G E
EG
Uges
Donald R A
DR
D000903:Antibiotics, Antineoplastic / Q000032:analysis* / Q000097:blood; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000032:analysis* / Q000097:blood; D015251:Epirubicin / Q000032:analysis* / Q000097:blood*; D006801:Humans; D016014:Linear Models; D012463:Saliva / Q000737:chemistry*; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D004317:Doxorubicin; C046579:4'-deoxydoxorubicinol